UREA, N-(2,4-BIS(1-METHYLETHYL)-3-PYRIDINYL)-N'-(1-BUTYL-1,2-DIHYDRO-4-(3-METHOXYPHENYL)-2-OXO-1,8-NAPHTHYRIDIN-3-YL)-, MONOHYDROCHLORIDE
Congenital Adrenal Hyperplasia
Millendo Therapeutics US, Inc.Small moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
12 Active assets in the Congenital Adrenal Hyperplasia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Solu-Cortef University of Texas Southwestern Medical Center | Phase 4 | A |
Cortisone Federico II University | Phase 4 | BBB |
Atumelnant Crinetics Pharmaceuticals Inc. | Phase 3 | BB |
FLUDROCORTISONE University of Texas Southwestern Medical Center | Phase 3 | BB |
DEXAMETHASONE Shanghai Jiao Tong University School of Medicine | Phase 4 | BB |
View all 21 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →